HRJR7T.jpg

Harnessing The Power of
NK Cells to Defeat Cancer

 

Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2021, moving towards broad patient access to cancer-defeating cures.

- Daniel Teper, Cytovia Therapeutics CEO

 

Cytovia In The News

 
Conference Crowd

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

“Precision CAR-NK Cells produced from induced pluripotent stem cells have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy and broad patient access. We expect to bring the first iPSC CAR-NKs to initial clinical trials starting in 2021.”

- Daniel Teper, Cytovia Therapeutics CEO

 

Cytovia In The News

 
Press Conference

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

News & Events

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

 

“Precision CAR-NK Cells produced from induced pluripotent stem cells have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy and broad patient access. We expect to bring the first iPSC CAR-NKs to initial clinical trials starting in 2021.”

- Daniel Teper, Cytovia Therapeutics CEO

 

News & Events

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

 

“Precision CAR-NK Cells produced from induced pluripotent stem cells have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy and broad patient access. We expect to bring the first iPSC CAR-NKs to initial clinical trials starting in 2021.”

- Daniel Teper, Cytovia Therapeutics CEO

 

“Precision CAR-NK Cells produced from induced pluripotent stem cells have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy and broad patient access. We expect to bring the first iPSC CAR-NKs to initial clinical trials starting in 2021.”

- Daniel Teper, Cytovia Therapeutics CEO

 

Media & Press Updates

Cytovia Therapeutics Wins Top Industry Award

March 1, 2025

Offsite Takeaways: Doing it the Cytovia Therapeutics Way

March 1, 2025

New Startup Changing The Game

March 1, 2025

 
three newspapers_edited.jpg

News & Events

June 24th, 2020

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

Hebrew University to Collaborate with Cytovia Therapeutics on Natural Killer Cell Research

March 18th, 2020

Webcast: BIO CEO & Investor Conference

February 12th, 2020

 

Subscribe Form

  • Facebook
  • Twitter
  • LinkedIn